Connect with us

Business

Trump admin draws unproven link between autism and Tylenol ingredient use during pregnancy

Published

on

Trump admin draws unproven link between autism and Tylenol ingredient use during pregnancy


In this photo illustration, Tylenol caplets are displayed on Sept. 22, 2025 in San Anselmo, California.

Justin Sullivan | Getty Images

The Trump administration on Monday drew an unproven link between autism and pregnant women’s use of acetaminophen, the active ingredient in one of the world’s most common over-the-counter pain relievers, Kenvue‘s Tylenol.

President Donald Trump said the Food and Drug Administration will issue a physician’s notice about the risk of patients using acetaminophen during pregnancy unless they have a fever. The agency will also start the process of changing the safety label for acetaminophen on Tylenol and similar products.

The moves clash with a bulk of scientific literature suggesting no causal link between autism and exposure to acetaminophen in the womb. 

Many over-the-counter drugs contain acetaminophen, but Tylenol is widely considered the safest treatment to take during pregnancy to relieve pain and fever, as long as patients use the recommended dose. 

“Taking Tylenol is not good,” Trump said during a press conference on Monday. “They are strongly recommending that women limit Tylenol use during pregnancy unless medically necessary. That’s for instance, in cases of extremely high fever, that you feel you can’t tough it out, you can’t do it.”

The Health and Human Services Department will encourage clinicians to “exercise their best judgment” around the use of acetaminophen during pregnancy by “prescribing the lowest effective dose with the shortest necessary duration and only when treatment is required,” the department’s Secretary Robert F. Kennedy Jr. said during the press briefing.

HHS will launch a nationwide campaign to inform patients about the alleged risk, Kennedy said.

In a statement Monday, Kenvue said it believes in “independent, sound science” that shows taking acetaminophen does not cause autism, and “we strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers.” Without the drug as an option, women may have to experience conditions like fever that are potentially harmful to both them and their babies, or use riskier alternatives, Kenvue said.

Untreated fever and pain during pregnancy can carry risks for both mother and infant, such as miscarriage, birth defects and high blood pressure, according to the Society for Maternal-Fetal Medicine.

FDA Commissioner Marty Makary suggested that treating a fever “can prolong the duration of illness in a young kid,” citing a study from Johns Hopkins, without further details.

“Maybe that’s because a fever is a body’s natural way of ridding an infection,” Makary said.

Trump, several times during the briefing, said “there’s no downside” to not taking Tylenol during pregnancy or in a baby’s early life.

FDA clears lesser-known drug

Also on Monday, the FDA approved a lesser-known drug, leucovorin, as a treatment for autism, Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz said during the briefing.

The agency is specifically updating leucovorin’s label for cerebral folate deficiency, which HHS said has been associated with autism. The change will allow children with autism to be treated with the drug, with continued use if kids show language, social or adaptive gains, according to an HHS release.

But HHS said leucovorin is not a cure for autism and may only lead to improvements in speech-related deficits for a subset of children with the disorder. State Medicaid programs will be able to cover the drug for autism after the label update. The NIH will also start trials to confirm the effects of leucovorin on the disorder, including studies into the medicine’s safety.

While promising, it is important to note that leucovorin is not a cure for ASD and may only lead to improvements in speech-related deficits for a subset of children with ASD. Furthermore, this treatment must be administered under close medical supervision and in conjunction with other non-pharmacological approaches for children with ASD (e.g., behavioral therapy). 

Leucovorin is a form of folate, a B vitamin, that is typically prescribed to counteract some medications’ side effects, including chemotherapy, and to treat vitamin B9 deficiency. Some early placebo-controlled clinical trials have shown that oral leucovorin, also known as folinic acid, has the potential to improve symptoms in children with autism spectrum disorder.

The Food and Drug Administration early Monday published a notice saying it is approving a version of leucovorin that was previously made by GSK, the Wall Street Journal reported. But as of Monday afternoon, the Federal Register’s website said it has received an “agency letter” asking to withdraw the notice.

In a statement, a GSK spokesperson said it does not intend to market leucovorin. The company marketed the drug from 1983 to 1999 under the name Wellcovorin, but the product was withdrawn from the market and has since been available as a generic drug. The spokesperson said label changes made to Wellcovorin will help allow generics already on the market to add this new approval for autism to their labeling.

Acetaminophen is the latest widely used and accepted treatment that Robert F. Kennedy Jr. has undermined at the helm of the Health and Human Services department, which oversees federal health agencies that regulate drugs and other therapies. Kennedy has also taken steps to change vaccine policy in the U.S., and has amplified false claims about safe and effective shots that use mRNA technology.

Kennedy has made autism a key focus of HHS, pledging in April that the agency will “know what has caused the autism epidemic” by September and eliminate exposures. He also said that month that the agency has launched a “massive testing and research effort” involving hundreds of scientists worldwide that will determine the cause.

Much of the scientific community agrees that autism results from a complex mix of genetic and environmental factors, making it unlikely that rising rates of the disorder are due to a single cause.

Kennedy said HHS expects several announcements over the coming years that inform parents about the underlying cause of autism and “potential paths for prevention and reversal.” He acknowledged that autism is a complex disorder caused by a combination of factors and said HHS is continuing to investigate other factors, such as vaccines.

“One area that we are closely examining … some 40% to 70% of mothers with autism believes that her child was injured by a vaccine,” Kennedy said. “President Trump believes that we should be listening to these mothers instead of gaslighting like prior administrations.”

Extensive research has debunked longstanding concerns that vaccines are linked to autism, a claim that Kennedy and other immunization critics have pushed for several years.

Research on acetaminophen use and autism

The Washington Post on Friday reported that Trump administration officials have been reviewing previous research that suggests a link between the use of acetaminophen during pregnancy and an increased risk of autism. The Post said that includes an August review by Mount Sinai and Harvard researchers on 46 earlier studies that suggest a link between prenatal exposure to the drug and increased risks of neurodevelopmental disorders, such as autism or attention deficit hyperactivity disorder, or ADHD. 

The review found the association is strongest when acetaminophen is taken for four weeks or longer, Dr. Andrea Baccarelli, one of its authors and dean of the faculty at the Harvard T.H. Chan School of Public Health, said in a statement. The review was funded by a grant from the National Institutes of Health.

“This biological evidence lends support to the possibility of a causal relationship between prenatal acetaminophen exposure and neurodevelopmental disorders, including autism,” Baccarelli said, adding that further research is needed to “confirm the association and determine causality.”

He said based on existing evidence, he believes that “caution about acetaminophen use during pregnancy—especially heavy or prolonged use—is warranted.” But Baccarelli said acetaminophen remains a critical tool for pregnant women and their physicians, as the drug is the only approved medication for pain and fever relief during pregnancy.

He said he and his colleagues recommend a “balanced approach based on the precautionary principle:” patients who need fever or pain reduction during pregnancy should take the lowest effective dose of the drug for the shortest possible duration, after consulting their physician about their individual risks and benefits of doing so. Baccarelli said he discussed that recommendation and the review’s findings with NIH Director Jay Bhattacharya and Kennedy in recent weeks.

The findings of the studies reviewed by the researchers are at odds with other robust studies, including one published last year in the Journal of the American Medical Association that found acetaminophen use during pregnancy was not linked to autism, ADHD or intellectual disability. Researchers analyzed health records of 2.5 million children in Sweden.

When researchers looked at the general population initially, there was a very small increased risk of the disorder in children whose mothers took the drug while pregnant. But researchers found no link after comparing siblings within the same family: one exposed to acetaminophen during pregnancy, and the other not.

As of Monday before the announcement, the FDA website said the agency had not found “clear evidence” that appropriate use of acetaminophen during pregnancy causes “adverse pregnancy, birth, neurobehavioral, or developmental outcomes.” The American College of Obstetricians and Gynecologists maintains that acetaminophen is safe during pregnancy when taken as directed and after consulting a health-care provider. 

Some parents have brought lawsuits claiming that they gave birth to children with autism after using the painkiller.

But a federal judge in Manhattan ruled in 2023 that some of those lawsuits lacked scientific evidence and later ended the litigation in 2024.

— CNBC’s Angelica Peebles contributed to this report



Source link

Business

Stock market today: Nifty50 above 26,100; BSE Sensex down over 140 points – The Times of India

Published

on

Stock market today: Nifty50 above 26,100; BSE Sensex down over 140 points – The Times of India


Stock market today (AI image)

Stock market today: Nifty50 and BSE Sensex, the Indian equity benchmark Indies, opened in red on Friday on lacklustre global and domestic cues. While Nifty50 was just above 26,100, BSE Sensex was down over 140 points. At 9:16 AM, Nifty50 was trading at 26,101.30, down 41 points or 0.16%. BSE Sensex was at 85,267.87, down 141 points or 0.16%.Indian equity markets are expected to move in a narrow range as investors remain cautious in the absence of any major domestic economy triggers.Dr. VK Vijayakumar, Chief Investment Strategist, Geojit Investments Limited says, “With only four more trading days left for the year 2025, what looked like a Santa rally, appears to be running out of steam. In the absence of fresh triggers like a US-India trade deal, the market is likely to consolidate around the present levels. Higher US GDP growth of 4.3% for the third quarter of 2025 is imparting resilience to the US market. The high and rising profitability of US companies, including the AI ones, might nudge other FIIs, particularly the fleet footed hedge funds, to increase selling in India in the near-term.” “The sustained buying by the cash rich DIIs will support the market and prevent a sharp pull back. The ideal investment strategy for investors now is to remain invested in high quality large caps and slowly accumulate them on declines. A rally in the market in the early stage of 2026 is on the cards. Investors should give high weightage to value while deciding to invest. Irrational valuations in some of the IPOs and the willingness of the newbie investors to buy stocks at excessive valuations are reflections of exuberance in the market.Asian markets saw modest gains on Friday amid thin trading conditions. Japanese and South Korean equities advanced, while several other regional markets remained closed for holidays. In the commodities market, silver surged to a record high, while gold traded close to its all-time peak.Oil prices edged higher on Friday after the United States stepped up economic pressure on Venezuelan oil exports and carried out airstrikes against Islamic State militants in northwest Nigeria at the request of the Nigerian government.On the institutional front, foreign portfolio investors were net sellers of Indian equities worth Rs 1,721 crore on Wednesday, while domestic institutional investors provided support by purchasing shares worth Rs 2,381 crore.(Disclaimer: Recommendations and views on the stock market, other asset classes or personal finance management tips given by experts are their own. These opinions do not represent the views of The Times of India)



Source link

Continue Reading

Business

PhysicsWallah, Ambuja Cement & more: Stock recommendations by brokers for today — check details – The Times of India

Published

on

PhysicsWallah, Ambuja Cement & more: Stock recommendations by brokers for today — check details – The Times of India


Goldman Sachs initiated its coverage of PhysicsWallah with a neutral rating and a target price of Rs 135. Analysts said the company is one of India’s largest edtech platforms, with a broadly equal mix of revenues from online and offline segments. They forecast a 24% compounded annual growth rate (CAGR) of revenue for FY25-FY30 (vs 38% for last two years), at mid-to-high end of India internet coverage, with 80%+ earnings before interest, taxes, depreciation, and amortisation (EBITDA) CAGR over this period. Analysts said they view such numbers as a function of PW’s strong top of the funnel organic traffic, a relatively benign competitive environment in India’s edtech sector, and PW’s pricing structure that allows it to penetrate deeper into multiple new education categories. They also warned that PW’s business model also has a negative working capital cycle, and forecast 100%+ free cash flow to net income for the company starting FY26.Avendus Spark initiated its coverage of LG Electronics with a reduce rating and a target price of Rs 1,536. Analysts said despite lower bargaining power and increasing customer choices due to competition, LG’s extensive reach remains a key strength and moat. The company has a robust in-house manufacturing capability and a third facility is in the pipeline to cater to the South Indian market and exports, which will also save logistics costs. They said the company is likely to face market share erosion, revenue impact and challenges in its niche premium/super-premium categories due to relatively new entrants.Nuvama has initiated its coverage of Knowledge Marine Engineering Works with a buy rating and a target price of Rs 2,500. Analysts said that India’s maritime industry is at an inflection point with unprecedented emphasis on infrastructure creation and inland waterways. KMEW enjoys a 50% order-win rate amid scarce competition and high entry barriers, delivers superior 35–40% EBITDA margin and is diversified across a spectrum of dredging, shipbuilding and ancillary services accounting for 43%, 11% and 46% of balance order book, respectively.HSBC has a buy rating on Ambuja Cement with the target price at Rs 700. Analysts said that the company’s board has approved the amalgamation of ACC and Orient Cement into Ambuja, with the completion expected within twelve months. The company’s management expects operational synergies to drive cost savings of at least Rs 100/tonne. Analysts see the amalgamation as a positive move for the companyInvestec has a buy rating on RBL Bank with the target price at Rs 430. Analysts said that the bank intends to deploy $1.5 billion of $3 billion infusion to retire high-cost liabilities and expects rating upgrades (AA- to AA+/AAA) to narrow its wholesale funding cost gaps vs larger peers. The lender expects to grow its loan book at 30% in FY27, led by wholesale, prime housing, and a pick-up in unsecured retail. Under the new expected credit loss (ECL) norms that is effective April 2027, the management expects a one-time impact of Rs 1,500 to Rs 1,700 crore (4% of post-dilution net worth) and a 20–25 basis points (100 basis points = 1 percentage point) rise in credit costs on a run-rate basis, partly offset by faster secured lending growth.(Disclaimer: Recommendations and views on the stock market, other asset classes or personal finance management tips given by experts are their own. These opinions do not represent the views of The Times of India)



Source link

Continue Reading

Business

Ruble surges in 2025: Russian currency emerges as top performer against US dollar; why it’s a headache for its war economy – The Times of India

Published

on

Ruble surges in 2025: Russian currency emerges as top performer against US dollar; why it’s a headache for its war economy – The Times of India


The Russian currency Ruble emerged as the top-performing major currency against the US dollar this year, surging 45% since January. This unexpected strength caught Russian officials off guard and poses challenges for the country’s war-affected economy. The currency is now trading around 78 per dollar, similar to levels before Russia’s Ukraine invasion, as reported by Economic Times.The surge comes from several factors. Russians are buying less foreign currency due to international sanctions. High interest rates have also made ruble investments more attractive to locals. The central bank kept rates very high from October last year until June this year, before reducing them by 5 points to 16 per cent.This strong performance has exceeded government expectations, which predicted an average rate of 91.2 per dollar for the year. The ruble has stayed strong despite lower oil prices and new sanctions from the US and Europe. This strength is actually causing problems by reducing the value of export earnings when converted to rubles.The Bank of Russia has been supporting the currency by selling foreign currency, particularly yuan and gold, from the National Wellbeing Fund. This is helping offset declining energy revenues, with oil and gas income dropping 22% in the first 11 months of 2023.The ruble’s impressive performance puts it among the world’s top five performing assets this year, alongside precious metals like platinum, silver, palladium, and gold. Central Bank Governor Elvira Nabiullina sees this strength as helpful in fighting inflation, noting that its positive effects on prices haven’t yet peaked.



Source link

Continue Reading

Trending